Bioxyne Limited (AU:BXN) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Bioxyne Limited announced a significant supply agreement expected to generate approximately $28 million over the next 24 months from pharmaceutical cannabis products, with the initial order valued at $1.6 million. The undisclosed customer, citing confidentiality and security reasons, has agreed to a fixed price for the term and has already paid a $900,000 deposit, reinforcing the company’s positive revenue forecast. Bioxyne delayed announcing this market-sensitive contract until certain conditions were met, ensuring the company could meet the customer’s demand and maintain confidentiality as per the agreement.
For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.